- Previous Close
9.23 - Open
9.24 - Bid 6.48 x 200
- Ask 11.62 x 200
- Day's Range
8.93 - 9.24 - 52 Week Range
2.69 - 10.88 - Volume
5,802 - Avg. Volume
23,536 - Market Cap (intraday)
97.007M - Beta (5Y Monthly) 0.90
- PE Ratio (TTM)
-- - EPS (TTM)
-5.51 - Earnings Date Nov 11, 2024 - Nov 15, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
19.00
Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. The company was incorporated in 1995 and is headquartered in Hayward, California.
benitec.comRecent News: BNTC
View More
Performance Overview: BNTC
Trailing total returns as of 9/30/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: BNTC
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: BNTC
View MoreValuation Measures
Market Cap
95.85M
Enterprise Value
45.26M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.77k
Price/Book (mrq)
2.03
Enterprise Value/Revenue
10.46k
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-49.60%
Return on Equity (ttm)
-91.68%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-22.37M
Diluted EPS (ttm)
-5.51
Balance Sheet and Cash Flow
Total Cash (mrq)
50.87M
Total Debt/Equity (mrq)
0.60%
Levered Free Cash Flow (ttm)
-11.68M
Research Analysis: BNTC
View MoreCompany Insights: BNTC
BNTC does not have Company Insights